June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Ebola Virus Persistence in Ocular Tissues and Fluids (EVICT) II Study:Cataract Surgery and RT-PCR Outcomes in Ebolavirus Disease Survivors
Author Affiliations & Notes
  • Jessica Shantha
    UCSF, UCSF Proctor Foundation , San Francisco, California, United States
  • Moges Teshome
    Lowell and Ruth Gess Eye Hospital, Freetown, Sierra Leone, Freetown, Sierra Leone
  • John Mattia
    Lowell and Ruth Gess Eye Hospital, Freetown, Sierra Leone, Freetown, Sierra Leone
  • Robert Garry
    School of Medicine, Tulane , New Orleans, Louisiana, United States
  • Matthew Jusu Vandy
    Lowell and Ruth Gess Eye Hospital, Freetown, Sierra Leone, Freetown, Sierra Leone
  • Steven Yeh
    Emory University, Atlanta, Georgia, United States
  • Footnotes
    Commercial Relationships   Jessica Shantha, None; Moges Teshome, None; John Mattia, None; Robert Garry, None; Matthew Vandy, None; Steven Yeh, None
  • Footnotes
    Support  Heed Foundation, Bayer Global Ophthalmology Awards Program
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 3608. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jessica Shantha, Moges Teshome, John Mattia, Robert Garry, Matthew Jusu Vandy, Steven Yeh; Ebola Virus Persistence in Ocular Tissues and Fluids (EVICT) II Study:Cataract Surgery and RT-PCR Outcomes in Ebolavirus Disease Survivors. Invest. Ophthalmol. Vis. Sci. 2017;58(8):3608.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Ebolavirus(EBOV) persistence after acute illness has been previously reported in the aqueous humor, which suggests the eye could be a potential reservoir for EBOV transmission. We report the baseline characteristics and visual outcomes of Ebolavirus Disease(EVD) survivors undergoing cataract surgery.

Methods : Baseline (cross-sectional) study from a prospective clinical cohort of EVD survivors with cataracts. Criteria for cataract surgery included: 1) negative EBOV PT-PCR anterior chamber paracentesis 2) visually significant cataract as determined by vision and ophthalmic exam. Patients were excluded if diagnosed with any ophthalmic condition that would preclude meaningful visual acuity improvement despite cataract surgery. Data collected consisted of demographic characteristics, ocular and medical history, and ophthalmic exam (slit lamp exam, dilated fundus exam, B-scan), serum EBOV IgG, and EBOV RT-PCR on intraocular fluid after removal of lens material. All surgeries were performed with strict infection control procedures for health care provider protection.

Results : Sixteen patients (EBOV IgG positive) met eligibility criteria for surgery: 62.5% were female with an average age of 31 years (range:12-70). Mean time from discharge from an Ebola treatment unit was 21 months (range:13-31); 14 (87.5%) eyes had a history of uveitis; and, median pre-op visual acuity (VA) was 20/1260 (range:20/80-LP). 56.2% had cataracts in the right eye. Cataract types included age-related nuclear sclerotic (3), posterior subcapsular (3), cortical (2), uveitic white cataract (5), mature cataract (1), combination (2). Cataract extraction, synechiolysis and posterior chamber intraocular lens implantation was performed without complication in all eyes. The median post-operative day 1 (POD) VA was 20/60 (range: 20/20-hand motion,p<0.05) with continued improvement at post-operative month 1 with median VA 20/30 (n=9;p<0.05). Two patients experienced transient elevated intraocular pressure on POD 1, which resolved with ocular hypotensives. Intraocular fluid immediately after cataract extraction tested negative for EBOV by RT-PCR in all eyes.

Conclusions : Cataract surgery, with strict infection control guidance, was safe, effective, and led to meaningful visual restoration in EVD survivors. Further studies are needed given the public health impact to eye care providers and patients.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×